Lack of association of the CD14/C-159T polymorphism with susceptibility and serological activity parameters of rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 35, Issue 1, 2006, Pages 20-22

  De La Fontaine, L ^a   Schwarz, M ^a   Plischke, H ^a   Kleindienst, N ^a   Gruber, R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CD14 ANTIGEN; CITRULLINE; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEALTH STATUS; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUBILITY;

ANTIGENS, CD; ANTIGENS, CD14; ARTHRITIS, RHEUMATOID; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES;

EID: 32644455671     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740500395260     Document Type: Article

References (15)

1. Wordsworth BP, Bell JI. The immunogenetics of rheumatoid arthritis. Springer Semin Immunopathol 1992;14:59-78.
2. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000;43:30-7.
3. Harney SM, Newton JL, Wordsworth BP. Molecular genetics of rheumatoid arthritis. Curr Opin Pharmacol 2003;3:280-5.
4. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
5. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
6. Dobrovolskaia MA, Vogel SN. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002;4:903-14.
7. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976-83.
8. Hubacek JA, Rothe G, Pitha J, Skodova Z, Stanek V, Poledne R, et al. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999;99:3218-220.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Patino R, Ibarra J, Rodriguez A, Yague MR, Pintor E, Fernandez-Cruz A, et al. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol 2000;85:1288-91.
11. Koenig W, Khuseyinova N, Hoffmann MM, Marz W, Frohlich M, Hoffmeister A, et al. CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002;40:34-42.
12. Hubacek JA, Stavek P, Pitha J, Skodova Z, Poledne R. CD14 (C-159→T) polymorphism and levels of C-reactive protein. Cas Lek Cesk 2003;142:174-6.
13. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001;167:5838-44.
14. Repo H, Anttonen K, Kilpinen SK, Palotie A, Salven P, Orpana A, et al. CD14 and TNFa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy. Scand J Rheumatol 2002;31:355-61.
15. Knijff-Dutmer E, Drossaers-Bakker W, Verhoeven A, van der Sluijs Veer G, Boers M, van der Linden S, et al. Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis 2002;61:603-7.